卵巢癌（OC）是世界范围内死亡率较高的妇科恶性肿瘤。 OC的不良预后主要归因于复发倾向。近年来，OC 死亡率呈下降趋势。这些有利的模式可能是由新型治疗方案的进步推动的。然而，这些新药在女性复发性 OC (ROC) 中的应用缺乏可视化分析。因此，我们的目的是对 ROC 治疗中不断演变的范式进行文献计量分析。有关 ROC 治疗的文献是从 MEDLINE 数据库和 Web of Science 核心合集 (WOSCC) 中系统收集的。检索到的文档以纯文本文件格式导出，文件被命名并保存到Java应用程序指定的路径中。使用Microsoft Excel（2010版）、Citespace（6.2.R4）和VOSviewer（1.6.19）进行数据分析，包括以下内容：1）年度发表趋势； 2）国家、机构和作者的贡献； 3）期刊和参考文献的共同引用； 4）关键词共现。共检索到MEDLINE发表文献914篇，WOSCC发表文献9980篇。多年来，有关 ROC 治疗的出版物的产量呈上升趋势。美国是这一领域的主要贡献者，德克萨斯大学系统脱颖而出，成为生产力最高的机构。 Giovanni Scambia 和 Maurie Markman 是 ROC 治疗领域的研究领导者。妇科肿瘤学杂志的引用频率最高。标题为“Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer”的参考文献在同被引网络中的中心度最高，为 0.14。关键词分析显示，目前ROC治疗的重点是铂类抗癌药物、紫杉醇、血管生成抑制剂(AIs)、免疫检查点抑制剂(ICIs)和聚(ADP-核糖)聚合酶抑制剂(PARPis)。各国在 ROC 治疗的进步方面发挥了重要作用。该领域的研究热点和趋势主要来源于妇科肿瘤领域的国际领先期刊和专业期刊。使用 AI 或（和）PARPis 维持治疗已成为 ROC 患者铂类化疗的重要补充。版权所有 © 2024 郝、宋、李和郭。

Ovarian cancer (OC) is a gynecological malignancy with a high mortality rate worldwide. The unfavorable prognosis of OC is mainly attributed to the recurrent propensity. Recently, mortality from OC has exhibited a downward trend. These favorable patterns are likely to be driven by advancements in novel therapeutic regimens. However, there is a lack of visualize analysis of the application of these new drugs on women with recurrent OC (ROC). Therefore, we aimed to provide a bibliometric analysis of the evolving paradigms in the ROC treatment.Documents on ROC treatment were systematically collected from the MEDLINE database and Web of Science Core Collection (WOSCC). The retrieved documents were exported in the plain text file format, and files were named and saved to the paths specified by the Java application. Microsoft Excel (version 2010), Citespace (6.2.R4) and VOSviewer (1.6.19) were used for data analysis, and included the following: 1) annual publication trend; 2) contributions of countries, institutions and authors; 3) co-citation of journals and references; and 4) co-occurrence of keywords.A total of 914 documents published in the MEDLINE and 9,980 ones in WOSCC were retrieved. There has been an upward trend in the productivity of publications on ROC treatment on by years. The United States was the leading contributor in this field, and the University of Texas System stood out as the most productive institution. Giovanni Scambia and Maurie Markman were the research leaders in the field of ROC treatment. The journal Gynecologic Oncology had the highest citation frequency. The reference entitled with "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer" got highest centrality of 0.14 in the co-citation network. Keyword analysis revealed that the focus of current ROC treatment was on platinum-based anticancer drugs, paclitaxel, angiogenesis inhibitors (AIs), immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).Scholars from a multitude of countries have been instrumental in the advancement of ROC treatment. The research hotspots and trend in the field of predominantly originated from leading international journals and specialized periodicals focused on gynecologic oncology. Maintenance therapy using AIs or (and) PARPis has emerged as a significant complement to platinum-based chemotherapy for patients with ROC.Copyright © 2024 Hao, Song, Li and Guo.